Physician profile
Sam Shaver
NPI 1093065377
$23,137.87
in general payments reported to CMS, 2019-2025
43 companies · $4,697 in 2025
The $4,697 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,734 · 2020: $1,001 · 2021: $1,503 · 2022: $3,094 · 2023: $4,614 · 2024: $4,494 · 2025: $4,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,505.94 |
| Education | $298.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,473.63 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $2,808.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,152.02 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Abbvie INC. | $2,045.17 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,993.13 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $1,680.64 | 2022-2025 | |
| Pfizer INC. | $724.49 | 2019-2025 | |
| Axsome Therapeutics, INC. | $720.91 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $629.52 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $534.27 | 2019-2022 | |
| Amarin Pharma, INC. | $487.86 | 2019-2022 | |
| Esperion Therapeutics, INC. | $422.80 | 2021-2022 | |
| Allergan, INC. | $407.27 | 2019-2020 | |
| Dexcom, INC. | $389.48 | 2022-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Phathom Pharmaceuticals, INC. | $385.38 | 2024-2025 | Voquezna |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $356.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $354.68 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $343.49 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $288.25 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.23 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $206.38 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $188.19 | 2019-2023 | Rotateq, Gardasil 9, Vaxelis |
| Verona Pharma, INC. | $156.11 | 2025 | Ohtuvayre |
| Medtronic, INC. | $122.30 | 2022-2025 | Intellis Adaptivestim |
| Mylan Specialty L.P. | $121.91 | 2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $111.95 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $101.94 | 2019-2023 | |
| Redhill Biopharma INC. | $97.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.02 | 2019-2024 | |
| Shield Therapeutics INC | $65.95 | 2024 | |
| Lundbeck LLC | $58.96 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $52.08 | 2022 | |
| Edwards Lifesciences Corporation | $48.75 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mirum Pharmaceuticals, INC. | $47.02 | 2025 | Cholbam |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.81 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $35.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.11 | 2019-2023 | |
| Daiichi Sankyo INC. | $22.50 | 2024 | Injectafer |
| Sanofi Pasteur INC. | $17.87 | 2019 | |
| Sumitomo Pharma America, INC. | $13.92 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $12.51 | 2023 | Heplisav-B |
| Ibsa Pharma INC. | $12.47 | 2022 | |
| Shire North American Group INC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.